Clinical trial
A Study of Two Anti-HIV Drug Combinations
NCT00002203 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002203 |
|---|---|
| Title | A Study of Two Anti-HIV Drug Combinations |
| Official title | A Randomized, Multicenter Study of Epivir 150 Mg Bid, Retrovir 200 Mg Tid and a Protease Inhibitor Vs 3TC 150 Mg/ZDV 300 Mg Fixed Dose Tablet Given Bid With a Protease Inhibitor in HIV-Infected Patients |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lamivudine/Zidovudine, Lamivudine, Zidovudine |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: